A Review of Factors That Influence Individual Compliance with Mass Drug Administration for Elimination of Lymphatic Filariasis

Abstract

BackgroundThe success of programs to eliminate lymphatic filariasis (LF) depends in large part on their ability to achieve and sustain high levels of compliance with mass drug administration (MDA). This paper reports results from a comprehensive review of factors that affect compliance with MDA.Methodology/Principal FindingsPapers published between 2000 and 2012 were considered, and 79 publications were included in the final dataset for analysis after two rounds of selection. While results varied in different settings, some common features were associated with successful programs and with compliance by individuals. Training and motivation of drug distributors is critically important, because these people directly interact with target populations, and their actions can affect MDA compliance decisions by families and individuals. Other important programmatic issues include thorough preparation of personnel, supplies, and logistics for implementation and preparation of the population for MDA. Demographic factors (age, sex, income level, and area of residence) are often associated with compliance by individuals, but compliance decisions are also affected by perceptions of the potential benefits of participation versus the risk of adverse events. Trust and information can sometimes offset fear of the unknown. While no single formula can ensure success MDA in all settings, five key ingredients were identified: engender trust, tailor programs to local conditions, take actions to minimize the impact of adverse events, promote the broader benefits of the MDA program, and directly address the issue of systematic non-compliance, which harms communities by prolonging their exposure to LF.Conclusions/SignificanceThis review has identified factors that promote coverage and compliance with MDA for LF elimination across countries. This information may be helpful for explaining results that do not meet expectations and for developing remedies for ailing MDA programs. Our review has also identified gaps in understanding and suggested priority areas for further research.

Can chemotherapy alone eliminate the transmission of soil transmitted helminths?

“…It is probable that certain groups are more likely to systematically reject treatment and extra effort is required to target these groups [45]. This phenomenon is the subject of ongoing work.…”

Directly observed treatment increases drug compliance in lymphatic filariasis mass drug administration

“…Actually the antifilariasis drugs were handed over to the health cadres, to be subsequently distributed to the residents. (17)(18)(19) The MDA program in the Pabean region used a combination of DEC, albendazole and paracetamol, administered once annually for a minimum of 5 years. The dose of DEC is 6 mg/ kgBW, albendazole 400 mg for all age groups, and paracetamol 10 mg/kgBW.…”

Improving Coverage and Compliance in Mass Drug Administration for the Elimination of LF in Two ‘Endgame’ Districts in Indonesia Using Micronarrative Surveys

“…Although the issue of low coverage is not a new one, it has become increasingly recognized as the 2020 deadline approaches for LF elimination. Recent reviews on factors associated with coverage and compliance with antihelmintic treatment highlight some of the pertinent issues that need addressing [8–10]. These reviews report similar findings across global and Indian-specific contexts.…”

“…Definitions related to persons receiving LF drugs and persons taking LF drugs vary significantly in the peer reviewed literature and in the field [8–10]. In the reality of MDA, directly observed treatment is not always implemented on the ground during MDA, and as a result, the WHO definition of drug coverage may not always reflect the true rate of those who took the treatment.…”